THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: A multicenter phase II study

European Journal of Haematology

Volumn 84, Issue 5, 2010, Pages 391-397

  Takamatsu, Yasushi ^a   Suzumiya, Junji ^a   Utsunomiya, Atae ^b   Maeda, Koichi ^c   Matsuoka, Hitoshi ^d   Suzushima, Hitoshi ^e   Tsukada, Junichi ^f   Shibata, Keisuke ^g   Tamura, Kazuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b IMAMURA BUN IN HOSPITAL   (Japan)

^c Kokuritsu Miyakonojo Hospital   (Japan)

^d Koga General Hospital   (Japan)

^e NTT West Kyushu Hospital   (Japan)

^f UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^g Fukuoka Postal Services Agency Hospital   (Japan)

Author keywords

Adult T cell leukemia lymphoma; Peripheral T cell lymphoma; Pirarubicin; THP COP

Indexed keywords

CYCLOPHOSPHAMIDE; PIRARUBICIN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HEART MUSCLE ISCHEMIA; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; T CELL LEUKEMIA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PREDNISOLONE; VINCRISTINE;

EID: 77951026143     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01411.x     Document Type: Article

References (17)

1. Anderson JR, Armitage JO, Weisenburger DD, and for the Non-Hodgkin's Lymphoma Classification Project. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol 1998 9 : 717 720.
2. Ohshima K, Suzumiya J, Kikuchi M. The World Health Organization classification of malignant lymphoma: incidence and clinical prognosis in HTLV-1-endemic area of Fukuoka. Pathol Int 2002 52 : 1 12.
3. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998 92 : 76 82.
4. Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008 26 : 4124 4130.
5. Niitsu N, Umeda M. Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. Eur J Haematol 1999 63 : 337 344.
6. Niitsu N, Khori M, Hayama M, Kajiwara K, Higashihara M, Tamaru J. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels. Clin Cancer Res 2005 11 : 697 702.
7. Aoki S, Tsukada N, Nomoto N, Maruyama S, Takahashi M, Moriyama Y, Shibata A, Aizawa Y. Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res 1998 17 : 465 470.
8. Mori M, Kitamura K, Masuda M, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Int J Hematol 2005 81 : 246 254.
9. Mori M, Niitsu N, Takagi T, Tomiyama J, Matsue T, Nakagawa Y, Okamoto R. Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2001 41 : 359 366.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999 17 : 1244 1253.
11. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009 27 : 453 459.
12. + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008 111 : 5496 5504.
13. Suzumiya J, Ohshima K, Tamura K, et al. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project. Ann Oncol 2009 20 : 715 721.
14. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007 25 : 5458 5464.
15. Mourad N, Mounier N, Brière J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008 111 : 4463 4470.
16. Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004 104 : 634 641. (Pubitemid 38970554)
17. Tsurumi H, Hara T, Goto N, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 2007 25 : 107 114.